ISIN | LU1540961247 |
---|---|
Valor Number | 35006956 |
Bloomberg Global ID | |
Fund Name | HBM UCITS (Lux) Funds-HBM Global Healthcare Fund P USD Cap |
Fund Provider |
HBM Partners AG
Zug, Schweiz Phone: +41 43 888 71 71 E-Mail: investorrelations@hbmpartners.com Web: www.hbmpartners.com |
Fund Provider | HBM Partners AG |
Representative in Switzerland |
FundPartner Solutions (Suisse) SA Genève 75 |
Distributor(s) | FundPartner Solutions (Suisse) S.A. |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The investment objective of the Sub-Fund is to achieve long-term capital gains, by pursuing a long/short strategy in the "healthcare" market. The goal is to generate a value trend that exceeds the performance of the SOFR (the “Benchmark”). No guarantee can be given that the investment objective will be achieved. |
Peculiarities |
Current Price * | 255.89 USD | 08.08.2025 |
---|---|---|
Previous Price * | 255.14 USD | 07.08.2025 |
52 Week High * | 293.00 USD | 16.09.2024 |
52 Week Low * | 225.43 USD | 08.04.2025 |
NAV * | 255.89 USD | 08.08.2025 |
Issue Price * | 255.89 USD | 08.08.2025 |
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 17,421,607 | |
Unit/Share Assets *** | 15,261,557 | |
Trading Information SIX |
YTD Performance | +0.49% |
31.12.2024 - 08.08.2025
31.12.2024 08.08.2025 |
---|---|---|
YTD Performance (in CHF) | -10.51% |
31.12.2024 - 08.08.2025
31.12.2024 08.08.2025 |
1 month | +3.39% |
08.07.2025 - 08.08.2025
08.07.2025 08.08.2025 |
3 months | +6.39% |
08.05.2025 - 08.08.2025
08.05.2025 08.08.2025 |
6 months | -3.79% |
10.02.2025 - 08.08.2025
10.02.2025 08.08.2025 |
1 year | -6.81% |
08.08.2024 - 08.08.2025
08.08.2024 08.08.2025 |
2 years | +6.39% |
08.08.2023 - 08.08.2025
08.08.2023 08.08.2025 |
3 years | +5.99% |
10.08.2022 - 08.08.2025
10.08.2022 08.08.2025 |
5 years | +17.70% |
12.08.2020 - 08.08.2025
12.08.2020 08.08.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Eli Lilly and Co | 8.71% | |
---|---|---|
UCB SA | 5.50% | |
Stryker Corp | 4.91% | |
Natera Inc | 4.72% | |
AbbVie Inc | 4.61% | |
Lonza Group Ltd | 4.42% | |
Intuitive Surgical Inc | 4.05% | |
The Cooper Companies Inc | 3.53% | |
Novo Nordisk AS Class B | 3.45% | |
Gilead Sciences Inc | 3.44% | |
Last data update | 30.06.2025 |
TER | 0.0165% |
---|---|
TER date | 31.01.2018 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.20% |
Ongoing Charges *** | 2.55% |
SRRI ***
|
|
SRRI date *** | 31.07.2025 |